NeoPharm Salute del bilancio
Salute finanziaria criteri di controllo 6/6
NeoPharm has a total shareholder equity of ₩166.1B and total debt of ₩0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are ₩181.9B and ₩15.8B respectively. NeoPharm's EBIT is ₩24.9B making its interest coverage ratio -5.8. It has cash and short-term investments of ₩110.2B.
Informazioni chiave
0%
Rapporto debito/patrimonio netto
₩0
Debito
| Indice di copertura degli interessi | -5.8x |
| Contanti | ₩110.16b |
| Patrimonio netto | ₩166.08b |
| Totale passività | ₩15.84b |
| Totale attività | ₩181.92b |
Aggiornamenti recenti sulla salute finanziaria
Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Mar 28
Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Dec 04
Recent updates
NeoPharm CO., LTD.'s (KOSDAQ:092730) Earnings Are Not Doing Enough For Some Investors
Sep 13NeoPharm (KOSDAQ:092730) Will Want To Turn Around Its Return Trends
Aug 07NeoPharm CO., LTD. (KOSDAQ:092730) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Jun 13Benign Growth For NeoPharm CO., LTD. (KOSDAQ:092730) Underpins Its Share Price
Apr 24NeoPharm's (KOSDAQ:092730) Earnings Are Weaker Than They Seem
Mar 25Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Mar 28What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Mar 15How Much Did NeoPharm's(KOSDAQ:092730) Shareholders Earn From Share Price Movements Over The Last Three Years?
Mar 02We're Watching These Trends At NeoPharm (KOSDAQ:092730)
Feb 18We're Not So Sure You Should Rely on NeoPharm's (KOSDAQ:092730) Statutory Earnings
Feb 08NeoPharm CO., LTD. (KOSDAQ:092730) Has Got What It Takes To Be An Attractive Dividend Stock
Jan 26An Intrinsic Calculation For NeoPharm CO., LTD. (KOSDAQ:092730) Suggests It's 31% Undervalued
Jan 15Will Weakness in NeoPharm CO., LTD.'s (KOSDAQ:092730) Stock Prove Temporary Given Strong Fundamentals?
Jan 04NeoPharm CO., LTD. (KOSDAQ:092730) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Dec 24What Is NeoPharm CO., LTD.'s (KOSDAQ:092730) Share Price Doing?
Dec 15Does NeoPharm (KOSDAQ:092730) Have A Healthy Balance Sheet?
Dec 04Would Shareholders Who Purchased NeoPharm's (KOSDAQ:092730) Stock Year Be Happy With The Share price Today?
Nov 23Analisi della posizione finanziaria
Passività a breve termine: A092730's short term assets (₩139.0B) exceed its short term liabilities (₩15.6B).
Passività a lungo termine: A092730's short term assets (₩139.0B) exceed its long term liabilities (₩263.6M).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: A092730 is debt free.
Riduzione del debito: A092730 has no debt compared to 5 years ago when its debt to equity ratio was 0.4%.
Copertura del debito: A092730 has no debt, therefore it does not need to be covered by operating cash flow.
Copertura degli interessi: A092730 has no debt, therefore coverage of interest payments is not a concern.